Related Experiment Videos
Crystallization and preliminary X-ray diffraction studies of human angiostatin
1Department of Chemistry, Michigan State University, East Lansing, MI 48824, USA.
Acta Crystallographica. Section D, Biological Crystallography
|February 22, 2002
Summary
Angiostatin, an angiogenesis inhibitor, shows promise as an anticancer drug. Researchers have successfully crystallized human angiostatin (K1-3) to enable high-resolution structural analysis for drug development.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
- Angiostatin is a potent inhibitor of angiogenesis, making it a potential anticancer therapeutic.
- Angiostatin is currently undergoing Phase I clinical trials.
Purpose of the Study:
- To obtain high-resolution structural data of human angiostatin (K1-3) through crystallization.
- To facilitate structure-based drug design for developing novel anticancer therapies.
Main Methods:
- Crystallization of human angiostatin (K1-3).
- Collection of high-resolution X-ray diffraction data.
- Determination of crystal space group and unit-cell parameters.
Main Results:
- Human angiostatin (K1-3) crystals were obtained.
- The crystals belong to the P4(1)2(1)2 space group.
- High-resolution data (1.75 A) were collected with favorable R(merge) (7%) and I/sigma(I) (19.5) values.
Conclusions:
- The successful crystallization and data collection provide a structural basis for understanding angiostatin's mechanism of action.
- This structural information is vital for the rational design of more effective angiogenesis inhibitors for cancer treatment.